1. Home
  2. Directory
  3. North Carolina
  4. Asheville
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1437101045

DR. RICHARD NORMAN LIND MD
Prescription History 1437101045
Internal Medicine - Hematology & Oncology in Asheville, NC

NPI Status: Active since May 16, 2006

Contact Information

53 S FRENCH BROAD AVE STE 40
ASHEVILLE, NC
ZIP 28801
Phone: (828) 274-7502
Fax: (828) 552-5661

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. RICHARD NORMAN LIND MD, an active Hematology & Oncology specialist practicing in Asheville, NC. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 84 documented patient claims. Among these therapy options, the most frequently utilized medication is Tamoxifen Citrate, which accounts for 36 claims alone.

Medication Index

A
E
L
T
No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 24.0
Days Supply 720
NC State Average Benchmarks
Peer Average Claims63.0
Peer Average 30-Day Fills145.4
Peer Average Days Supply4,334
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.8% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $129.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.23

State Avg Cost Per Claim

$24.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 13.0
Days Supply 390
NC State Average Benchmarks
Peer Average Claims84.0
Peer Average 30-Day Fills126.3
Peer Average Days Supply3,570
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 86.9% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,652.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$695.64

State Avg Cost Per Claim

$781.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 45.0
Days Supply 1,350
NC State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills133.2
Peer Average Days Supply3,966
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.0% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $298.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.00

State Avg Cost Per Claim

$26.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 36
30-Day Fills 62.0
Days Supply 1,860
NC State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills92.3
Peer Average Days Supply2,748
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $659.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.32

State Avg Cost Per Claim

$31.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. RICHARD NORMAN LIND MD provides transparency into local medical care patterns within Asheville, NC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.